Sheets Smith Wealth Management reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 57.0% during the 4th quarter, Holdings Channel reports. The fund owned 2,507 shares of the company’s stock after selling 3,326 shares during the quarter. Sheets Smith Wealth Management’s holdings in Eli Lilly and were worth $423,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the company. HT Partners LLC increased its position in shares of Eli Lilly and by 1.4% during the 4th quarter. HT Partners LLC now owns 4,428 shares of the company’s stock valued at $748,000 after purchasing an additional 61 shares during the period. KMG Fiduciary Partners LLC increased its position in shares of Eli Lilly and by 2.0% during the 3rd quarter. KMG Fiduciary Partners LLC now owns 3,392 shares of the company’s stock valued at $502,000 after purchasing an additional 67 shares during the period. Veracity Capital LLC increased its position in shares of Eli Lilly and by 3.2% during the 3rd quarter. Veracity Capital LLC now owns 2,358 shares of the company’s stock valued at $349,000 after purchasing an additional 73 shares during the period. Prestige Wealth Management Group LLC increased its position in shares of Eli Lilly and by 11.6% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 722 shares of the company’s stock valued at $107,000 after purchasing an additional 75 shares during the period. Finally, Platform Technology Partners increased its position in shares of Eli Lilly and by 2.1% during the 3rd quarter. Platform Technology Partners now owns 3,715 shares of the company’s stock valued at $550,000 after purchasing an additional 75 shares during the period. Institutional investors own 69.85% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction on Monday, January 11th. The stock was sold at an average price of $185.49, for a total transaction of $40,807,800.00. Following the completion of the sale, the insider now owns 111,003,815 shares of the company’s stock, valued at $20,590,097,644.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.09% of the stock is currently owned by company insiders.

Several brokerages have recently issued reports on LLY. Sanford C. Bernstein started coverage on Eli Lilly and in a research report on Tuesday, November 10th. They set a “market perform” rating and a $150.00 price target on the stock. Mizuho lifted their target price on Eli Lilly and from $156.00 to $164.00 and gave the stock a “neutral” rating in a report on Wednesday, December 16th. Truist lifted their target price on Eli Lilly and from $182.00 to $200.00 in a report on Tuesday. Berenberg Bank started coverage on Eli Lilly and in a report on Tuesday, September 29th. They issued a “hold” rating and a $144.00 target price on the stock. Finally, Wolfe Research upgraded Eli Lilly and from a “peer perform” rating to an “outperform” rating and lifted their target price for the stock from $147.00 to $183.00 in a report on Thursday, December 10th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $171.13.

LLY opened at $185.50 on Thursday. The stock has a market cap of $177.45 billion, a price-to-earnings ratio of 30.31, a PEG ratio of 1.52 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $117.06 and a 1 year high of $189.30. The company has a current ratio of 1.36, a quick ratio of 1.06 and a debt-to-equity ratio of 3.27. The stock has a fifty day moving average price of $161.85 and a 200 day moving average price of $153.50.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Sunday, November 1st. The company reported $1.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.17). The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.87 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. Eli Lilly and’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.48 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 7.21 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 10th. Investors of record on Friday, February 12th will be given a dividend of $0.85 per share. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.74. The ex-dividend date is Thursday, February 11th. This represents a $3.40 dividend on an annualized basis and a yield of 1.83%. Eli Lilly and’s dividend payout ratio (DPR) is presently 49.01%.

Eli Lilly and Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.

Featured Story: How Investors Use a Balance Sheet

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.